Patient Safety & Systems-Based Practice

Medication reconciliation: admission, transfer, discharge

Clinical Overview and When to Suspect Medication Discrepancies

— Up to 60% of admitted patients have at least one unintended medication discrepancy on admission

— Adverse drug events (ADEs) cause ~1.3 million ED visits/year in the US; ~50% of post-discharge ADEs are preventable through proper reconciliation

— Highest-risk transitions: discharge home from hospital, ICU-to-floor transfer, hospital-to-SNF

— Patient on >5 chronic medications (polypharmacy) or >10 (hyperpolypharmacy)

— Multiple prescribers (PCP + cardiologist + pain clinic) or multiple pharmacies

— Cognitive impairment, low health literacy, limited English proficiency

— Recent formulary substitution (e.g., metoprolol tartrate ↔ succinate confusion)

— Recently discharged from another facility in past 30 days

— Use of high-alert medications: anticoagulants, insulin, opioids, chemotherapy, immunosuppressants

Medication reconciliation (med rec) is the formal process of comparing a patient's current medication list against new orders at every transition of care — admission, intra-hospital transfer, and discharge — to identify and resolve discrepancies (omissions, duplications, dose errors, interactions).

Joint Commission National Patient Safety Goal 03.06.01 mandates med rec at all care transitions; it is one of the most frequently cited deficiencies on hospital surveys.

Epidemiology of harm:

When to be highly suspicious that reconciliation has failed:

High-risk drug classes for transition errors (mnemonic "A-PINCH"): Anticoagulants, Potassium/electrolytes, Insulin, Narcotics/sedatives, Chemotherapy, Heparins/anti-infectives.

Board pearl: The single most common admission discrepancy is omission of a chronic home medication — particularly inhalers, eye drops, topicals, OTCs, and "as-needed" agents that patients forget to mention. Specifically asking about each category reduces omission rate by ~40%.

Step 3 management: When a discrepancy is found, do not silently "correct" it — document the source, contact the prescribing clinician or outpatient pharmacy, and reconcile in the chart with a rationale note.

Presentation Patterns and Key History

— Beta-blocker withheld on admission in a heart failure or post-MI patient → rebound tachycardia, hypertension, ischemia within 24–48 h

— Clonidine omission → severe rebound hypertension, often with diaphoresis and headache

— Levodopa missed doses in Parkinson disease → rigidity, aspiration, neuroleptic malignant–like syndrome

— SSRI/SNRI abruptly stopped → discontinuation syndrome (flu-like, paresthesias, dizziness)

— Chronic steroid omission → adrenal crisis with hypotension, hyponatremia

— Home insulin not resumed → DKA or HHS in inpatients made NPO then forgotten

— Patient continues both old and new antihypertensive after a class switch → symptomatic hypotension, AKI within 1–2 weeks

— Duplicate anticoagulation (DOAC plus continued warfarin) → major bleed

— PPI or stress-ulcer prophylaxis inappropriately continued indefinitely

— Inhaled corticosteroid dropped from COPD/asthma regimen → readmission for exacerbation

— Use at least two sources: patient interview + pill bottles + outpatient pharmacy fill records + EHR med list + family/caregiver

— Ask explicitly: "Do you take any eye drops, inhalers, patches, injections, creams, vitamins, herbals, or as-needed medications?"

— Confirm actual adherence ("How many days in the last week did you miss your lisinopril?") rather than prescribed regimen

— Document allergies with reaction type — "penicillin → rash at age 5" vs anaphylaxis changes empiric choices

Med rec failures rarely present as a single dramatic event; instead they surface as subacute clinical deterioration that the team initially attributes to the primary illness.

Classic admission-reconciliation failure patterns:

Discharge-reconciliation failure patterns:

Key history elements at every transition:

Key distinction: A prescribed medication list (what the chart says) is not the same as the best possible medication history (BPMH) — the verified list of what the patient is actually taking. BPMH is the gold standard reference for reconciliation.

Physical Exam Findings and Bedside Assessment

— Transdermal patches: fentanyl, nitroglycerin, clonidine, estradiol, rivastigmine, scopolamine — check behind the ear, upper arm, chest, back, hip; missed patches cause both omission (if removed) and overdose (if multiple in place)

— Insulin pump or CGM sensor on abdomen/arm → patient is on basal-bolus, not just oral agents

— Implanted devices: pacemaker, ICD, intrathecal pump, deep brain stimulator → implies specific drug regimens

— Medic-alert bracelet → anticoagulant, diabetes, adrenal insufficiency, anaphylaxis history

— Bradycardia + hypotension in a previously hypertensive patient: ? double-dosed beta-blocker or clonidine

— Tachycardia + tremor + diaphoresis: missed beta-blocker, alcohol/benzo withdrawal, or thyroid med excess

— Pinpoint pupils + somnolence: unrecognized chronic opioid or fentanyl patch

— Gingival hyperplasia → phenytoin, cyclosporine, amlodipine

— Cushingoid features → undisclosed chronic steroids; adrenal crisis risk if not continued

— Bruising/petechiae → anticoagulant or antiplatelet not on the chart

— Brief Mini-Cog or orientation check — patients who fail are unreliable historians for their own med list; escalate to caregiver/pharmacy verification

— Verify drug, dose, fill date, pills remaining vs expected (adherence estimate)

— Look for multiple bottles of the same drug from different pharmacies (duplication risk)

Med rec is principally a cognitive/process task, but the physical exam provides corroborating clues that the home regimen is incomplete, wrong, or causing harm.

Bedside artifacts of the home regimen:

Signs suggesting a medication is missing or in excess:

Cognitive screen at admission for any elder:

Inspect any pill bottles or "brown bag" the patient brought:

CCS pearl: On a CCS case, ordering "Obtain medication list from outpatient pharmacy" and "Medication reconciliation" at admission and discharge are scored items — they are not optional background tasks.

Diagnostic Workup — Identifying the Discrepancy

— 1. Collect the BPMH from ≥2 sources

— 2. Compare to admission/transfer/discharge orders

— 3. Clarify discrepancies with prescriber or patient

— 4. Reconcile — document resolution in the chart

— 5. Communicate the final list to patient and next provider

— Omission: home med not ordered (most common)

— Commission: a med ordered that the patient does not actually take

— Wrong dose/frequency/route

— Therapeutic duplication: two drugs in the same class (e.g., lisinopril + losartan)

— Drug–drug or drug–disease interaction introduced by the new order set

— Outpatient pharmacy fill history (gold standard for adherence) — call or use e-prescribing network (Surescripts)

— EHR external records / Care Everywhere for prior hospitalizations

— State Prescription Drug Monitoring Program (PDMP) — mandatory check for controlled substances at admission and discharge in nearly all US states

— INR, anti-Xa, drug levels (digoxin, phenytoin, vancomycin, tacrolimus) to corroborate stated dosing

— HbA1c, lipid panel, TSH to confirm whether reported chronic therapy is achieving expected effect

— Hypokalemia + metabolic alkalosis → undisclosed diuretic

— Anion-gap acidosis → metformin, salicylate, alcohol

— Prolonged INR not on warfarin → occult DOAC or supratherapeutic dosing

The "diagnostic workup" in med rec is a structured comparison rather than a lab panel. Standard 5-step process:

Types of discrepancies to classify:

Useful "labs" of med rec — supporting data to validate the list:

Red-flag findings on initial labs that signal hidden meds:

Board pearl: A discrepancy is clinically significant if continuing the error for 48 hours would likely cause harm — these must be resolved before the patient leaves the ED or transfers from ICU; non-significant ones can be reconciled within 24 hours per most institutional policies.

Diagnostic Workup — Advanced Verification and Tools

— Pharmacist-led medication history: reduces admission discrepancies by ~50–80% in RCTs; recommended for all high-risk patients (≥10 meds, ≥65 yo, recent transition, high-alert drugs)

— Direct contact with outpatient pharmacy — verify last fill date, dose, quantity dispensed

— PCP office call — most reliable for recently changed regimens

— Transfer summary from prior facility — must list drug, dose, route, frequency, indication, start/stop dates, and reason for any change

— e-prescribing / Surescripts data integrated into EHR (covers ~95% of US retail prescriptions but not samples, mail-order in some plans, or cash-pay controlled substances)

— PDMP query — required at admission for opioids/benzos; in many states required at every discharge prescription of a controlled substance

— Bar-code medication administration (BCMA) at bedside verifies the right drug reaches the right patient (5 rights), but does not validate the underlying list

— Non-English-speaking patient → use certified medical interpreter (not family); ad-hoc interpretation is a documented source of med errors

— Homeless or undomiciled → contact shelter clinic, free-clinic records; ask about samples and borrowed medications

— Recently discharged from another hospital → obtain that discharge summary before finalizing new orders

— Clinical trial participation → contact study coordinator; blinded study drug interactions must still be considered

— Each medication should list: name, dose, route, frequency, indication, last dose taken, prescriber, source of verification

— Allergies: substance + reaction + severity + date

When the standard history fails (cognitive impairment, polypharmacy, transfer from outside hospital), escalate to advanced verification:

Tools and technology:

Special verification scenarios:

Documentation standards:

Key distinction: A "medication list" is data; a "medication reconciliation note" is a clinical act — it must explicitly state that each home med was continued, held, modified, or discontinued, and why. A reconciliation without rationale is not a reconciliation.

Risk Stratification and Reconciliation Strategy by Transition

— Age ≥65 with ≥5 chronic medications

— Any high-alert drug: warfarin, DOACs, insulin, chemotherapy, immunosuppressants, opioids, antiepileptics

— Renal/hepatic impairment requiring dose adjustment

— Recent transition (<30 days from prior hospitalization or SNF stay)

— Cognitive impairment or limited health literacy

— Discharge to SNF or LTAC — receiving facility errors are common

— Admission: build the BPMH; for each home med decide continue, hold, modify; document indication for any held med (e.g., "metformin held — contrast study planned"); flag time-critical meds (Parkinson, antiepileptics, immunosuppressants, insulin) for first-dose timing

— Intra-hospital transfer (e.g., ICU → floor, OR → PACU → floor): re-verify drips, reconcile stress-dose steroids, DVT prophylaxis, antibiotics — ~25% of errors occur at transfer, often from order-set differences between units

— Discharge: produce a single, patient-facing reconciled list distinguishing NEW, CHANGED, STOPPED, UNCHANGED; explicitly explain duration for time-limited courses (antibiotics, steroid tapers, DVT prophylaxis)

— Stop stress-ulcer prophylaxis initiated in ICU if no ongoing indication

— Stop inpatient sleep aids, laxatives, antiemetics not needed at home

— Re-evaluate PPIs, benzodiazepines, anticholinergics per Beers criteria in elders

Not all transitions carry equal risk; resource allocation should be risk-stratified.

High-risk patients warranting pharmacist-driven reconciliation:

Transition-specific strategies:

Deprescribing opportunities at discharge:

Step 3 management: Discharge med rec must include (1) reconciled list, (2) patient teach-back, (3) follow-up appointment within 7–14 days, (4) communication to PCP within 24–48 hours. Missing any of these is the most common Step 3 wrong answer in "what is the next best step at discharge" stems.

Pharmacotherapy — High-Risk Classes Requiring Explicit Reconciliation

— Confirm indication, target INR or DOAC dose, last dose, renal function

— On switching warfarin ↔ DOAC: overlap rules differ — warfarin → DOAC, start when INR <2.0; DOAC → warfarin, bridge with overlap until INR therapeutic ×2 days

— Periprocedural holds: apixaban hold 24–48 h (low/high bleed risk); warfarin hold 5 days; document resume date

— Hold metformin for iodinated contrast if eGFR <30 or AKI risk; resume after 48 h with stable creatinine

— Hold SGLT2 inhibitors ≥3 days before surgery (euglycemic DKA risk)

— Convert sliding-scale to basal-bolus for inpatients eating; resume home regimen at discharge unless A1c indicates change

— Continue beta-blockers perioperatively if chronically prescribed (abrupt withdrawal is a class I AHA recommendation against)

— ACEi/ARB: hold morning of major surgery to prevent intraop hypotension; resume within 48 h

— Statins: continue throughout admission; do not interrupt

— Levodopa: time-critical, give within 30 min of scheduled dose, never NPO without alternative (rotigotine patch)

— Antiepileptics: maintain levels; IV equivalents (levetiracetam, valproate, fosphenytoin) available

— SSRIs/SNRIs: do not abruptly stop except fluoxetine (long half-life)

— Lithium: hold if AKI, NSAIDs added, or volume-depleted; resume with normal renal function

Certain drug classes generate disproportionate transition errors; each requires a deliberate reconciliation script.

Anticoagulants:

Insulin and antihyperglycemics:

Cardiovascular:

Neuro/psych:

Steroids: Any patient on ≥5 mg prednisone for ≥3 weeks in the past year needs stress-dose coverage for major illness/surgery.

Opioids: Calculate morphine milligram equivalents (MME); check PDMP; co-prescribe naloxone if MME ≥50 or concurrent benzodiazepine.

Board pearl: The most tested error is omitting chronic beta-blocker at admission in an ACS or CHF patient — withdrawal precipitates tachycardia, ischemia, and arrhythmia within 24–48 hours.

Procedures and Process — Executing Reconciliation in Practice

— Triage nurse/clerk obtains initial list → MD or pharmacist creates BPMH with ≥2 sources → each home med dispositioned continue / hold / modify / discontinue with documented reason → orders entered → patient/family informed of any held meds

— Sending team writes transfer reconciliation note: active drips, scheduled meds, PRNs, antibiotics with day-of-therapy, anticoagulation status, DVT prophylaxis, stress-ulcer prophylaxis indication

— Receiving team re-verifies within 4 h; reconciles against ward order sets (e.g., default heparin protocols differ between ICU and floor)

— Generate after-visit summary (AVS) with reconciled list in patient-friendly language (drug, purpose, dose, frequency, duration, NEW/CHANGED/STOPPED tag)

— Perform teach-back: patient or caregiver verbalizes each new med's purpose and dose

— e-prescribe to a single pharmacy when possible; verify insurance coverage and copay for new high-cost meds (DOACs, biologics) before discharge to prevent non-fills

— Send discharge summary with reconciled list to PCP within 24–48 h; schedule follow-up within 7–14 days (within 7 days for HF, COPD, recent ACS)

— Discharge to SNF: include MAR-ready orders with start/stop dates and indications; SNF nurses cannot administer without complete orders

— Against-medical-advice (AMA) departure: still provide reconciled list and prescriptions — does not waive duty

— Hospice transition: deprescribe non-comfort meds (statins, antihypertensives if asymptomatic, bisphosphonates); ensure symptom-control regimen

Med rec is a process intervention, not a procedure, but executing it well at each transition follows a structured workflow.

Admission workflow (within 24 h, sooner for ICU/high-risk):

Transfer workflow:

Discharge workflow:

Special situations:

CCS pearl: On any CCS case ending in discharge, the order set should include "Medication reconciliation," "Discharge instructions," "Schedule follow-up," and "Notify primary care physician" — these are reproducibly scored counseling/safety items.

Special Populations — Elderly and Renal/Hepatic Impairment

— Beers Criteria (AGS 2023) drugs to avoid or use cautiously: long-acting benzodiazepines, first-gen antihistamines (diphenhydramine), tricyclics, muscle relaxants, glyburide, sliding-scale insulin alone, PPIs >8 weeks without indication, anticholinergics

— STOPP/START criteria: structured deprescribing/prescribing tool — discharge is a key opportunity to apply

— Anticholinergic burden score ≥3 → higher delirium and fall risk; tally diphenhydramine, oxybutynin, amitriptyline, paroxetine

— Fall risk meds: benzos, opioids, antihypertensives causing orthostasis, hypoglycemics — reconcile after every fall

— Recalculate eGFR (or CrCl by Cockcroft–Gault for drug dosing) at every transition; AKI during hospitalization mandates re-dosing

— DOACs: apixaban preferred in CKD; dabigatran avoid if CrCl <30; rivaroxaban avoid if CrCl <15

— Metformin: avoid if eGFR <30; reduce if 30–45

— Gabapentin, pregabalin, baclofen, lithium, digoxin, allopurinol, colchicine — all renal-dosed; commonly missed

— NSAIDs: avoid in CKD stage ≥3 and in elders generally

— Avoid or reduce acetaminophen (max 2 g/day in cirrhosis), statins (rosuvastatin and pravastatin safer), most benzos (lorazepam, oxazepam, temazepam OK — no CYP metabolism), opioids (use lower doses, avoid tramadol, codeine)

— Avoid in advanced cirrhosis: NSAIDs (HRS risk), ACEi/ARBs in decompensation, metformin in Child–Pugh C

Older adults are the highest-risk population for medication-related harm at transitions — they take more drugs, clear them slower, and have more cognitive/sensory barriers to self-reporting.

Geriatric-specific reconciliation issues:

Renal impairment adjustments:

Hepatic impairment:

Step 3 management: Every elder discharged on ≥1 new psychoactive med (opioid, benzo, sleep aid, antipsychotic) requires a documented fall-risk review, taper plan, and follow-up within 7 days; failure to do so is a Step 3 distractor trap.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Use LactMed and current FDA Pregnancy and Lactation Labeling Rule (PLLR) narratives rather than old A/B/C/D/X categories

— Reconcile at first prenatal visit: stop teratogens (ACEi/ARB, warfarin >6 weeks, isotretinoin, methotrexate, valproate, topiramate, mycophenolate, statins, NSAIDs after 20 weeks)

— Continue/swap appropriately: levothyroxine (often increase ~30%), insulin, labetalol/nifedipine for HTN, low-dose aspirin for preeclampsia prevention from 12 weeks if risk factors

— Antiepileptics: lamotrigine and levetiracetam preferred; do not abruptly stop — seizure risk to mother and fetus outweighs most teratogen risk

— Postpartum reconciliation: many meds restartable; check lactation compatibility before discharge

— All doses weight-based (mg/kg) with weight in kg only — pounds-vs-kg errors are sentinel events

— Reconcile liquid concentrations (e.g., amoxicillin 250 mg/5 mL vs 400 mg/5 mL) and provide dosing syringe, never household teaspoon

— Confirm immunization status as part of med rec at every well visit and admission

— At adolescent transitions: ask privately about contraception, mental health meds, substance use — parental list may be incomplete

— Transgender patients: confirm gender-affirming hormone regimens (estradiol, spironolactone, testosterone) — often omitted from charts; perioperative continuation generally safe with VTE prophylaxis

— Oncology patients: chemotherapy schedule, growth factors, antiemetics, prophylactic antimicrobials (acyclovir, PJP prophylaxis) — coordinate with oncologist before any med change

— Solid-organ transplant: tacrolimus/cyclosporine/sirolimus levels, MMF dose, prophylactic valganciclovir, TMP-SMX — never modify without transplant team

— HIV: continue ART without interruption; check for drug–drug interactions with new inpatient meds (rifampin, PPIs, statins)

Pregnancy and lactation:

Pediatrics:

Other subgroups:

Board pearl: In pregnancy, abrupt discontinuation of SSRIs, antiepileptics, or insulin causes more harm than the drugs themselves — reconcile, do not reflexively stop.

Complications and Adverse Outcomes of Failed Reconciliation

— ~20% of patients experience an ADE within 3 weeks of discharge; about two-thirds are preventable or ameliorable

— ADEs account for ~5% of 30-day readmissions and a higher fraction of preventable readmissions

— Anticoagulants, insulin/hypoglycemics, and opioids together cause >60% of ED visits for ADEs in elders

— Major bleeding — duplicate anticoagulants, missed dose hold for procedures, unrecognized DOAC + antiplatelet combo

— Thromboembolism — anticoagulant held at admission and never restarted; classic 30-day stroke after AFib admission

— Hypoglycemia — sulfonylurea continued during NPO status or with reduced PO intake post-discharge

— Hyperkalemia — ACEi + ARB + spironolactone + potassium supplement stacked across providers

— Serotonin syndrome — SSRI continued while linezolid, tramadol, or methylene blue added

— QT prolongation/TdP — methadone + ondansetron + fluoroquinolone + azole stacked

— Adrenal crisis — chronic prednisone omitted during acute stress

— Withdrawal syndromes — benzodiazepines, opioids, alcohol-related GABAergics, clonidine, baclofen

— Sentinel event reporting to Joint Commission for any death/permanent harm from med error

— Malpractice exposure — failure to obtain BPMH is a recognized standard-of-care breach

— CMS Hospital Readmissions Reduction Program penalties for excess 30-day readmissions, many driven by med-related issues

Failed med rec generates a recognizable spectrum of adverse drug events (ADEs) — both ADEs of commission and adverse drug withdrawal events (ADWEs) of omission.

Quantifying harm:

High-impact clinical complications:

System-level consequences:

Key distinction: An adverse drug reaction (ADR) is harm from a drug used appropriately; a medication error is a process failure that may or may not reach the patient. Both are reportable, but root-cause analysis differs — ADRs feed pharmacovigilance, errors feed system redesign.

When to Escalate — Pharmacist, Specialist, and System Consults

— ≥10 chronic medications

— Any high-alert drug requiring titration (warfarin, insulin, antiepileptics, immunosuppressants)

— Significant renal/hepatic impairment with multi-drug regimen

— Suspected drug–drug interaction generating new symptoms

— TPN, chemotherapy, or complex pediatric dosing

— Limited English proficiency without family caregiver

— Transplant pharmacy/team before any immunosuppressant change

— Oncology before holding or substituting any antineoplastic

— Cardiology/EP for device-related antiarrhythmics, sotalol, dofetilide

— HIV pharmacist for ART interactions

— Psychiatry for clozapine (REMS, ANC monitoring), MAOIs, lithium near toxicity

— Suspected acute overdose, intentional or accidental

— Massive ingestion of any high-risk drug

— Withdrawal syndromes requiring antidote (flumazenil rarely, naloxone, physostigmine, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors)

— Report errors via the institutional event-reporting system even if no harm reached the patient (near-miss)

— Sentinel events trigger root cause analysis (RCA) within 45 days per Joint Commission

— Patterns of errors prompt failure mode and effects analysis (FMEA) for prospective process redesign

— Patient on chronic opioids + benzodiazepines with respiratory depression → monitored bed or step-down with continuous pulse oximetry

— Insulin pump patient → endocrine consult; do not disconnect without basal coverage plan

— DOAC + major bleed → emergent reversal protocol, ICU

Escalation is appropriate whenever the reconciling clinician's expertise or time is exceeded by the patient's complexity.

Trigger thresholds for clinical pharmacist consultation:

Trigger thresholds for specialist contact:

Trigger for poison control / toxicology (1-800-222-1222 in US):

Patient-safety pathways:

Inpatient triage decisions tied to med rec:

Step 3 management: When a serious med error is identified mid-admission, the correct next step is (1) stabilize the patient, (2) disclose the error to patient/family per the institution's transparent disclosure policy, (3) file an event report, (4) reconcile the list to prevent recurrence — in that order.

Key Differentials — Other Causes of Med-List Discrepancies

— Pharmacy substitution / formulary change: metoprolol tartrate dispensed as succinate (or vice versa); generic name change patient does not recognize (e.g., "I take the white pill, not lisinopril")

— Therapeutic interchange by the inpatient pharmacy (omeprazole ↔ pantoprazole) — chart shows different drug than home label

— Hospital order-set defaults that auto-add or auto-discontinue (e.g., admission order set adds heparin DVT prophylaxis; discharge order set drops home anticoagulant unless reconciled)

— Dose rounding to commercially available strengths (warfarin 7.5 mg → 5 + 2.5)

— Mail-order vs retail — patient has 90-day supply at home but EHR shows only retail fills

— Sample medications dispensed by clinic — not in any pharmacy database

— Patient takes differently than prescribed ("I only take the lisinopril when my BP feels high") — adherence issue, not reconciliation error per se, but must be documented and addressed

— A drug on the chart not at home is not always omission — it may have been stopped by PCP last week

— A drug at home not on the chart is not always commission — patient may have stopped it after side effect

— The most recent fill is not always the current regimen — doses change between fills

Not every apparent discrepancy is a reconciliation failure; mimics must be recognized to avoid unnecessary changes.

Same-category causes (process within med-management chain):

Common reconciliation myth-busting:

Key distinction: A discrepancy is a difference between sources; a medication error requires that the difference be unintended and clinically meaningful. The reconciling clinician's job is to convert discrepancies into intentional, documented decisions — not merely to make lists match.

Key Differentials — Symptoms Mimicking Med-Related Harm

— Hypoglycemia, hypotension, bradycardia, bleeding, confusion/delirium, falls, AKI, hyperkalemia, QT prolongation, withdrawal syndromes

— Sepsis — hypotension and confusion overlap with sedative excess or antihypertensive duplication

— Acute MI / decompensated HF — fatigue, dyspnea overlap with beta-blocker excess or diuretic shortage

— Stroke / TIA — focal deficit may be confused with phenytoin/lithium toxicity

— Hypothyroid/hyperthyroid flare — fatigue or tachycardia mimic drug effect

— Electrolyte abnormalities from disease (SIADH from pneumonia) vs drug-induced (SSRI, thiazide)

— Infection-driven delirium vs anticholinergic burden

— Acute alcohol or illicit substance use mimicking withdrawal or overdose of prescribed agents

— Step 1: re-pull the BPMH and compare to current MAR — was any chronic med dropped or duplicated?

— Step 2: check timing — symptom onset within 24–72 h of admission/transfer/discharge raises suspicion of med-related cause

— Step 3: targeted labs/levels — INR, drug level, electrolytes, glucose, renal function

— Step 4: query PDMP and pharmacy fills for unsanctioned use (opioids, benzos)

— Step 5: if med-related cause excluded, pursue primary disease workup

When a patient deteriorates after a transition, distinguish a reconciliation failure from disease progression or new pathology.

Symptoms commonly attributed (correctly) to med errors:

Mimics to consider before attributing to reconciliation:

Systematic approach when a post-transition patient deteriorates:

Board pearl: Postoperative delirium in an elder is more often due to anticholinergic, benzodiazepine, opioid, or steroid effects than to "underlying dementia" — always review the MAR before ordering brain imaging in this scenario.

Secondary Prevention — Building a Reconciliation-Safe Discharge

— Single, written, reconciled medication list in patient's preferred language with NEW/CHANGED/STOPPED/UNCHANGED tags and indications

— Teach-back confirmation for every new high-alert med (anticoagulant, insulin, opioid, immunosuppressant)

— Pill organizer or blister pack for patients with ≥5 meds or cognitive concerns

— Pharmacy fulfillment confirmed before discharge — "meds-to-beds" programs cut 30-day readmissions

— Naloxone co-prescribed for any opioid prescription ≥50 MME/day or with concurrent benzodiazepine

— Anticoagulation plan: drug, dose, duration, monitoring (INR schedule for warfarin), bleeding-precaution counseling, follow-up clinic appointment

— Steroid taper schedule written explicitly with dates

— Antibiotic stop date specified (avoid open-ended courses)

— Stop inpatient-only drugs: stress-ulcer PPI, scheduled antiemetics, sleep aids, stool softeners

— Reassess chronic PPIs, benzos, sliding-scale insulin alone, anticholinergics per Beers

— Consolidate duplicate therapy from multiple specialists

— Discharge summary to PCP within 24–48 h including reconciled list, pending labs, follow-up plan, and rationale for every med change

— For SNF transfer: complete MAR-ready orders with indications and stop dates

— For specialist hand-off: highlight medication changes that affect their domain (e.g., new anticoagulant to cardiology)

Secondary prevention in med rec = preventing the next error and the next readmission through deliberate discharge design.

Core elements of a reconciliation-safe discharge bundle:

Deprescribing at discharge — the safest med is one the patient no longer needs:

Communication to next provider:

Step 3 management: The single highest-yield discharge intervention shown to reduce 30-day readmissions is the combined bundle of pharmacist-led reconciliation + teach-back + 7–14-day follow-up + PCP communication — not any single element alone.

Follow-Up, Monitoring, and Patient Counseling

— Heart failure, COPD, recent ACS: in-person or telehealth within 7 days

— New anticoagulant: INR check within 3–5 days for warfarin; clinic call within 1 week for DOAC tolerance

— New insulin or sulfonylurea: glucose log review at 1 week

— New psychotropic: clinical check at 1–2 weeks, then 4 weeks

— Routine medical admission: PCP within 7–14 days

— Post-op: surgeon at standard interval plus PCP within 2 weeks for chronic-disease med resumption

— ACEi/ARB/diuretic: BMP at 1–2 weeks for K+, Cr

— Statin: LFTs only if symptomatic; lipid panel at 6–12 weeks

— Lithium, valproate, phenytoin, digoxin: drug level + organ function at 1–2 weeks

— Thyroid med change: TSH at 6 weeks

— Immunosuppressants: trough levels per transplant protocol

— DOAC: renal function every 6–12 months (more often if CKD)

— Purpose, dose, schedule, duration, key side effects, what to do if a dose is missed

— When to call: symptoms specific to the regimen (bleeding on anticoagulant, hypoglycemia symptoms, swelling on ACEi)

— Avoid drug interactions: NSAIDs with anticoagulants/ACEi; grapefruit with calcineurin inhibitors and some statins; St. John's wort broadly

— Storage: insulin refrigeration, controlled-substance locking, child safety

— Disposal: DEA take-back days; FDA flush list for select opioids

— Transitional care management (TCM) CPT codes 99495/99496 reimburse interactive contact within 2 business days and face-to-face within 7–14 days

— Chronic care management for ≥2 chronic conditions with monthly care-plan oversight

Follow-up cadence after a transition should be driven by medication risk, not just diagnosis.

Recommended post-discharge follow-up windows:

Monitoring parameters by class:

Patient counseling essentials:

Health-systems supports:

CCS pearl: On any CCS case with a new chronic medication, advancing the clock and ordering the appropriate monitoring lab at the right interval (e.g., BMP 1 week after starting ACEi) is a scored action.

Ethical, Legal, and Patient Safety Considerations

— Patients have the right to understand each new medication, its purpose, risks, benefits, and alternatives — discharge prescriptions without counseling can constitute inadequate consent

— For off-label prescribing (common with antipsychotics, gabapentinoids), disclose off-label status

— Capacity assessment: a delirious or cognitively impaired patient cannot consent to a new high-risk med; obtain surrogate decision-maker per state hierarchy

— Joint Commission and most state laws require disclosure of harmful errors to patients

— Apology and disclosure are protected from admission as evidence in many states' "apology laws"

— Do not blame individuals during disclosure; describe what happened and the plan to prevent recurrence

— PDMP query required at admission and at discharge controlled-substance prescribing in most states

— Sentinel events (death or permanent harm from medication error) → Joint Commission notification and RCA within 45 days

— Suspected drug diversion by staff → report to pharmacy leadership, DEA (Form 106), and state board

— Suspected prescription forgery or doctor-shopping by patient → not a mandated report in most states, but document and consider PDMP-driven counseling

— The discharging physician is legally responsible for ensuring a safe handoff, including a reconciled list and timely communication to the next provider

— Failure to communicate a critical pending result or med change is a leading malpractice claim

— Patients may refuse a discharge medication — document the refusal, explain consequences, offer alternatives

— Do not stop chronic meds without the patient's understanding, even at another provider's request — confirm with original prescriber

Med rec sits at the intersection of patient safety, informed consent, and professional duty, and Step 3 routinely tests these edges.

Informed consent at transitions:

Transparent disclosure of errors:

Mandatory reporting and regulatory considerations:

Transition-of-care liability:

Patient autonomy and deprescribing:

Step 3 management: When you discover that a prior team's med error caused harm, the first correct action is honest disclosure to the patient and event reporting — never concealment or quiet correction.

High-Yield Associations and Rapid-Fire Facts

Joint Commission NPSG 03.06.01 — reconcile medications at all transitions of care.

IHI "5 Million Lives" campaign and WHO High 5s identified med rec as a core intervention.

Best Possible Medication History (BPMH) = verified from ≥2 sources, gold standard for admission.

MARQUIS toolkit (SHM) — evidence-based bundle reducing discrepancies by ~50%.

Pharmacist-led admission med rec: reduces clinically significant errors by ~50–80%.

Meds-to-beds: reduces 30-day readmissions ~15–20% in HF/COPD populations.

Top three drug classes for ED visits from ADEs in elders: anticoagulants, insulin/oral hypoglycemics, opioids.

High-alert drugs (ISMP list): anticoagulants, insulin, opioids, neuromuscular blockers, chemo, concentrated electrolytes (KCl, hypertonic saline), epidural/intrathecal agents.

Beers Criteria 2023 — avoid in elders: long-acting benzos, first-gen antihistamines, sliding-scale insulin alone, glyburide, NSAIDs chronically, PPIs >8 weeks without indication.

STOPP/START criteria — explicit deprescribing/prescribing rules for older adults.

Time-critical meds (give within 30 min of scheduled dose): Parkinson drugs, antiepileptics, immunosuppressants, anticoagulants, insulin, antibiotics for sepsis.

Stress-dose steroids: prednisone ≥5 mg ≥3 weeks in past year → cover for major illness/surgery.

Anticoagulation reversal: warfarin → 4-factor PCC + vitamin K; dabigatran → idarucizumab; apixaban/rivaroxaban → andexanet alfa or 4-factor PCC.

Naloxone co-prescription: opioid MME ≥50 or concurrent benzo.

DOAC renal cutoffs: apixaban most CKD-tolerant; dabigatran avoid if CrCl <30.

Discharge follow-up timing: HF/COPD/ACS within 7 days; routine within 14 days.

TCM CPT codes: 99495 (moderate complexity, 14-day visit), 99496 (high complexity, 7-day visit).

CMS Hospital Readmissions Reduction Program — penalties for excess 30-day readmissions in HF, AMI, pneumonia, COPD, CABG, THA/TKA.

Board pearl: The two transitions with the highest error rate are admission (omissions) and discharge (additions, duplications, and patient understanding failures); intra-hospital transfer is third.

Board Question Stem Patterns

— A 72-yo on chronic carbidopa-levodopa is admitted for pneumonia; 36 h later develops rigidity, hyperthermia, autonomic instability → answer: resume home Parkinson regimen immediately (NMS-like syndrome from levodopa omission), give rotigotine patch if NPO.

— Post-op day 2 patient on chronic metoprolol succinate develops HR 130, BP 180/100, chest pain → answer: restart home beta-blocker (was inadvertently omitted on admission orders).

— Patient discharged on apixaban; 1 week later presents with hematuria; review reveals home warfarin never stopped → answer: stop warfarin, reverse with vitamin K, check INR; root cause = failed discharge reconciliation.

— 80-yo, 14 meds including diphenhydramine for sleep, oxybutynin, lorazepam; falls and hip fracture → answer: deprescribe anticholinergics and benzodiazepines per Beers; physical therapy; vitamin D.

— Patient on chronic prednisone 7.5 mg for RA admitted for cholecystectomy without stress-dose steroids → postop hypotension, hyponatremia → answer: IV hydrocortisone 100 mg, continue stress-dose taper.

— Elder admitted with eGFR 25; ordered standard-dose gabapentin → develops somnolence, myoclonus → answer: reduce gabapentin per renal function.

— Patient brings white pills he calls "blood pressure pill"; chart says lisinopril 20; pharmacy fill shows lisinopril 10 → answer: verify with outpatient pharmacy and patient before continuing; correct dose error.

— HF patient discharged on new sacubitril/valsartan; what is the most appropriate follow-up? → answer: clinic visit within 7 days plus BMP at 1–2 weeks.

— You realize the prior team gave heparin to a patient on full-dose apixaban for 2 days; patient now has GI bleed → answer: stabilize, disclose to patient, file event report, reconcile and prevent.

Stem 1 — Admission omission causing decompensation:

Stem 2 — Beta-blocker withdrawal:

Stem 3 — Discharge duplication:

Stem 4 — Polypharmacy fall in elder:

Stem 5 — Adrenal crisis from steroid omission:

Stem 6 — Renal-dose miss:

Stem 7 — Pharmacy substitution confusion:

Stem 8 — Discharge follow-up question:

Stem 9 — Disclosure scenario:

Board pearl: When the stem describes a clinical deterioration within 24–72 h of any care transition, suspect med reconciliation failure before ordering imaging.

One-Line Recap

High-yield recap bullets:

Medication reconciliation is the structured comparison of a patient's verified home regimen against current orders at every transition of care — admission, transfer, and discharge — with explicit documentation of what is continued, held, modified, or discontinued and why, because most preventable post-transition harm comes from omissions, duplications, and miscommunication, not from new pathology.

BPMH from ≥2 sources is the foundation; pharmacist-led reconciliation in high-risk patients cuts clinically significant errors by 50–80%.

Highest-risk transitions are admission (omissions of chronic meds, especially beta-blockers, levodopa, steroids, insulin, anticoagulants) and discharge (duplications, additions, patient misunderstanding); intra-hospital transfer is third.

High-alert drug classes drive most serious harm — anticoagulants, insulin, opioids, immunosuppressants, antiepileptics, chemotherapy; each requires deliberate reconciliation, dose review against renal/hepatic function, and explicit monitoring.

A reconciliation-safe discharge bundle = single reconciled list with NEW/CHANGED/STOPPED tags, teach-back, meds-to-beds when possible, PCP communication within 24–48 h, follow-up within 7–14 days (within 7 days for HF/COPD/ACS), naloxone co-prescription when opioid MME ≥50, and clear deprescribing of inpatient-only meds.

Board pearl: When a stem describes clinical deterioration within 24–72 hours of any care transition — bradycardia, hypotension, bleeding, hypoglycemia, delirium, withdrawal, NMS-like syndrome, or adrenal crisis — review the medication reconciliation before chasing new diagnoses, and remember that on Step 3 the correct action after identifying an error is to stabilize, disclose transparently, file an event report, and reconcile to prevent recurrence — never silently correct.